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In this report, we describe the case of a 67-year-old woman with metastatic pancreatic uterine leiomyosarcoma.
She underwent a total hysterectomy and adnexectomy in December 2009. The resected uterine specimen was
characterized as a leiomyosarcoma. The patient was free of disease until November 2010, when three pulmonary
tumoral lesions detected by follow-up chest computed tomography were diagnosed as metastatic lesions. Wedge
resections and enucleoresection of the pulmonary tumoral nodules were performed, and the patient received
adjuvant chemotherapy. Ten months after the lung resection, an abdominal examination showed two tumoral masses
in the pancreas and no extrapancreatic recurrence. In April 2014, a pylorus-preserving pancreaticoduodenectomy was
performed. To date, the patient is alive, without any evidence of recurrence, and she has received chemotherapy.
Surgery can be considered in cases in which the pancreas is a unique metastatic site or even in cases with resectable
oligometastases.
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Uterine leiomyosarcoma (LMS) is a rare malignancy
with high metastatic potential. Patients with metastatic
or recurrent disease have a poor prognosis with limited
treatment options. The 5-year survival rates are 53% in
patients with stage I uterine LMS and 8% in those with
stages II through IV disease [1,2]. The most common
sites of metastatic LMS are the lung, the peritoneal cavity
and the liver [3,4]. A case of pancreatic metastasis from a
uterine LMS is rare [5,6]. Ogura et al. identified, in a
literature review, 25 cases of LMS metastases to the
pancreas, of which 7 cases were from a primary uterine
tumor [7]. In this report, we describe a case of a patient
with metastatic pancreatic uterine LMS.
Case presentation
A 67-year-old womanwith a medical history of hyper-
tension and hyperthyroidism presented to our hospital
with postmenopausal vaginal bleeding in 2009. A trans-
vaginal ultrasound showed a tumoral mass in the uterine
wall that was initially interpreted as a leiomyoma. In* Correspondence: irinel.popescu220@gmail.com
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unless otherwise stated.December 2009, she underwent a total hysterectomy and
bilateral adnexectomy. The surgically resected uterine spe-
cimen was characterized as a LMS (pT1c) with immuno-
histochemistry results positive for smooth muscle actin
(SMA) and desmin and a Ki-67 level of 30%. No adjuvant
radiochemotherapy was administered, but a follow-up
examination every 6 months was recommended. The pa-
tient was free of disease until November 2010, when three
pulmonary tumoral lesions 7 mm, 8.34-mm and 5 mm in
size, respectively, in the inferior lobe of the left lung were
detected by follow-up chest computed tomography (CT)
(Figure 1). To clarify the differential diagnosis between a
primary lung tumor and metastatic disease, the multi-
disciplinary panel decided to perform surgery.
Wedge resections and enucleoresection of the lung
tumoral nodules were performed in November 2011.
The histopathological examination of the resected lung
specimen revealed the presence of spindle-shaped cells
with a high mitotic count. The immunohistochemistry
was positive for SMA and desmin and negative for CD10,
MNF116 antibody and estrogen receptor/progesterone
receptor, and her Ki-67 level was 30%, thus clarifying the
diagnosis of a metastatic LMS. Postoperatively, the
patient received chemotherapy consisting of one cycle ofhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Chest computed tomography. The pulmonary nodular
tumor invasion.
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gemcitabine + vinorelbine (six cycles).
The regular follow-up CT scan obtained in July 2011,
10 months after the lung resection, showed two tumoral
masses in the pancreas at the junction of the head and
body. Whole-body positron emission tomography (PET)
performed in September 2011 (Figure 2) showed hetero-
geneous enhancement at the level of the pancreatic head
with metabolic activity, indicating malignant potential ofFigure 2 Positron emission tomography/computed tomography
revealed a mass in the pancreatic head with metabolic activity.the lesions, and no evidence of extrapancreatic meta-
static lesions.
The oncological context and the multiplicity of the
pancreatic lesions following the metastatic pulmonary
disseminations oriented the diagnosis towards pancreatic
metastases rather than a primary pancreatic tumor. In
terms of the biohumoral markers, the carcinoembryonic
antigen (CEA) and carbohydrate antigen (CA 19-9)
levels were as follows: 2 ng/ml; CA 19-9, 14 U/ml; how-
ever, an above upper limit level of chromogranin A could
have allowed a differential diagnosis of a primary pancre-
atic neuroendocrine tumor.
Because of the previous episode of lung metastases,
which suggested systemic dissemination, probably with
other occult metastatic lesions, the oncological panel
decided on systemic chemotherapy. In September 2011,
the patient was switched to a combination of gemcita-
bine (1,800 mg/m2) plus dacarbazine (500 mg/m2). PET/
CT performed in December 2013 showed a slight increase
in the size of the pancreatic lesions and no signs of extra-
pancreatic recurrence. Because acquired chemoresistance
was suspected and because the disease was apparently
limited to the pancreas, a decision was made to perform a
pancreatic resection. In April 2014, a pylorus-preserving
pancreaticoduodenectomy was performed (Figure 3).
Microscopically, the surgically resected pancreatic speci-
men showed features similar to those of the uterine LMS.
The immunohistochemical studies showed that the neo-
plastic cells were positive for SMA and desmin and
negative for chromogranin and synaptophysin.
The patient’s postoperative course was uneventful, and
she was discharged on the 12th postoperative day. To date,
the patient is alive, without any evidence of recurrence.
Discussion
Pancreatic isolated metastases are a rare condition, most
frequently originating from primary renal cell carcinomasFigure 3 Surgical specimen from the pancreaticoduodenectomy.
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A, Doxorubicin; BO, Bilateral salpingo-oophorectomy; Br, Brachytherapy; Ca, Carboplatin; Ci, Cisplatin; Cy, Cyclophosphamide; DP + Spl, Distal pancreatectomy and splenectomy; E, Epirubicin; LO, Left oophorectomy; LR,
Liver wedge resection; Om, Omentectomy; PH, Partial hysterectomy; PPPD, Pylorus-preserving pancreaticoduodenectomy; Rth, Radiotherapy; SP, Segmental pancreatectomy; TH, Total hysterectomy. FNA-papillary cystadenoma
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been reported to be 3% to 11% [9,10]. A uterine sarcoma
metastasized to the pancreas is an extremely rare condi-
tion which ensures that the decision regarding treatment
is difficult and nonstandardized. The decision is deter-
mined by an attending multidisciplinary oncology team.
Differentiation of a primary pancreatic adenocarcin-
oma or of neuroendocrine tumors from a metastatic
pancreatic tumor is required to perform neoadjuvant
therapy. CT and magnetic resonance imaging are used
for the evaluation of the pancreatic mass. Highly vascu-
larized tumors are more likely to be metastases than pri-
mary tumors, which are hypovascular. The difficulty lies
in distinguishing the tumors, on the basis of imaging,
between pancreatic metastatic tumors and pancreatic
neuroendocrine tumors, which are hypervascular as well
[11]. Percutaneous fine-needle aspiration (FNA) is help-
ful in the preoperative differential diagnosis between a
primary and metastatic pancreatic tumor. However,
the published data have shown a difference between
the immunohistochemical findings on the endoscopic
ultrasound-guided FNA (EUS-FNA) and the final im-
munohistochemistry results from the resected specimen.
The survival benefit of the resection of pancreatic me-
tastases has been demonstrated. Reddy and Wolfgang
[12], in a systemic review of the literature, evaluated 243
patients who had undergone radical pancreatic resection
for metastatic disease and concluded that the effective-
ness of pancreatic resection for a metastatic tumor is
dependent on the tumor biology of the primary cancer. In
other case reports [3,5,6,10,13-17], authors have described
good long-term survival following an aggressive surgical
approach, indicating a possible benefit of surgery in the
metastatic setting for selected cases (Tables 1 and 2).
In our patient, the long interval between the detection
of the pancreatic mass and its resection (33 months),
during which time the patient was managed by subse-
quent cycles of chemotherapy, provided the reason for
the oncologist’s and surgeon’s reluctance to resort to
surgery, questioning its benefit in a secondary metastatic
setting. A wait-and-see attitude regarding chemotherapy
was preferred, and the decision to perform surgery was
taken as a result of suspected chemoresistance after a long
interval of stable disease.
Conclusions
Surgery can be considered in the pancreas as a unique
metastatic site or even in cases with resectable oligome-
tastases. We hypothesize that a long disease-free interval
following resection of a primary tumor might be an indi-
cator of a more indolent tumor biology or chemores-
ponsiveness, and thus we question the possibility of the
surgical benefit for these select cases.Consent
Written informed consent was obtained from the patient
for publication of this Case report. A copy of the written
consent is available for review by the Editor-in-Chief of
this journal.
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